BeyondSpring, Inc.
As of Oct 22, 2026, BeyondSpring is in Stage 4, the downtrend phase, now in week 18 (since Jun 22, 2026). It closed at $0.45, 81.1% below its 52-week high and below its 200-day average, which is falling.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BYSI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BYSI among Biotechnology468th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …468 | BYSI | Stage 4 · wk 18 | 11 | −38.8% |
BeyondSpring: quick answers
What stage is BeyondSpring in?
As of Oct 22, 2026, BeyondSpring (BYSI) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 22, 2026 and is in week 18. What the four stages mean
Is BeyondSpring in an uptrend?
No. BeyondSpring is in a Stage 4 downtrend. It trades 65.9% below its 200-day average, which is falling.
How far is BeyondSpring from its 52-week high?
BeyondSpring closed at $0.45 on Oct 22, 2026, 81.1% below its 52-week high of $2.35. Its 52-week low is $0.45.
How has BeyondSpring performed over the past year?
As of Oct 22, 2026, BeyondSpring is down 79.8% over the past year and down 72.4% so far in 2026.
Which sector and industry is BeyondSpring in?
BeyondSpring is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.